Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Inclusion Criteria

• Subject is of either gender between 12 and 70 years of age, inclusive.
• Subject (or parent/legal guardian) has the ability and willingness to sign a written informed consent.
• Subject has a diagnosis of chronic (≥1 year), stable atopic dermatitis (AD)
• Subject has ≥ 5% and ≤ 30% body surface area (BSA) of AD involvement excluding the scalp and groin.
• Subject has an Investigator's Global Assessment (IGA) score of moderate (3) atopic dermatitis on the 5-point IGA (0-4) scale.
• For selected photography sites, subject has a target lesion of 25 to 200 cm2 in surface area on the trunk, upper extremities or lower extremities with a Baseline Signs of AD score of ≥ 6 and ≤ 12.
• Subject is in good general health without clinically significant hematological, cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or malignant disease, as determined by the investigator.
• Subject has suitable venous access for blood sampling.
• Subject is able and willing to complete the study and to comply with all study instructions and attend the necessary visits.
• Male subjects and their partners must agree and commit to use a barrier method of contraception throughout the study and for 90 days after last study drug application.
• A negative urine pregnancy test result for all Women of child bearing potential (WOCBP) at the Screening Visit and Baseline Visit.
• Sexually active women must agree to use the following throughout the study and for 30 days after last study drug application. WOCBP who are not sexually active at Baseline and become sexually active must identify a plan for contraception.
• One of these highly effective contraception methods Intrauterine device (IUD); hormonal (injections, implants, transdermal patch, vaginal ring); tubal ligation; partner vasectomy, OR
• Oral contraceptives WITH a barrier method (listed below), OR
• Two barrier forms of contraception (listed below) Male or female condom; diaphragm; cervical cap; contraceptive sponge.
• Males subjects must refrain from sperm donation during the study treatment period and until 90 days after last study drug application.

Exclusion Criteria

• Female subject who is breast feeding, pregnant, or planning to become pregnant.
• Subject who has an IGA score of 2 (mild) or 4 (severe).
• Subject with history of known or suspected intolerance to the drug product excipients.
• Subject has any clinically significant active infection in the investigator's opinion. This includes active impetigo at any AD lesion.
• Subject has known Hepatitis-B, Hepatitis-C, or HIV infection.
• Subject has excessive body or facial hair that would interfere with the evaluation of safety or with the diagnosis or assessment of AD.
• Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality that would result in the inability to evaluate the AD lesions.
• Subject has clinically significant or severe allergies that in the investigator's opinion would interfere with participation in the study.
• Subject has known intolerability to topical treatments e.g., reports excessive burning/stinging or pain with use of topical treatments.
• Subject has an active or potentially recurring skin conditions(s) other than AD that in the investigator's opinion would interfere with participation in the study.
• Subject has unstable AD consistent with a requirement for high-potency corticosteroids.
• Subject has used dupilumab (Dupixent) within 12 weeks prior to the Baseline Visit.
• Subject has used any biologic therapy, other than dupilumab, within 28 days prior to the Baseline Visit.
• Subject has used systemic (oral, IV or IM) corticosteroids within 28 days prior to the Baseline Visit. Intra-articular injection for arthroses allowed.
• Subject has used topical anti-pruritics (e.g., PDE4 inhibitors) within 28 days prior to the Baseline Visit.
• If